RNA polymerase mutants with improved performance

By introducing amino acid mutations at specific sites of T7 RNA polymerase, an improved performance RNA polymerase mutant was constructed, which solved the problems of by-product impact and thermal stability balance, achieved the improvement of enzyme activity and yield, and reduced dsRNA by-products and Immunogenicity meets the needs of mRNA vaccines and drug research.

WO2024235228A1PCT designated stage expired Publication Date: 2024-11-21WUHAN HANHAI NEW ENZYMES BIOLOGICAL TECH CO LTD

Patent Information

Application Number
PCT/CN2024/093147
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-24
Filing Date
2024-05-14
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The existing T7 RNA polymerase produces by-products, such as dsRNA, during RNA synthesis, which affects the effectiveness of mRNA vaccines and drug research. The existing mutants have thermal stability and activity balance problems in performance improvement, which cannot fully meet the growing research needs.

Method used

By introducing amino acid mutations at specific sites of T7 RNA polymerase, such as I217L, S397W, S430P, S633P, Q786L, C723E, and A724N, we construct improved RNA polymerase mutants to improve enzyme activity, thermal stability and in vitro transcription yield , reduce dsRNA by-products and immunogenicity.

Benefits of technology

It has achieved more than 47% increase in enzyme activity, improved thermal stability, improved in vitro transcription yield and 3' terminal consistency, reduced dsRNA by-products, reduced immunogenicity, and met a variety of research needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093147_21112024_PF_FP_ABST
    Figure CN2024093147_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are a series of RNA polymerase mutants with improved performance. The mutants, compared with an amino acid sequence of a parental RNA polymerase, have one or more amino acid mutations at positions 121, 223, 632, 217, 397, 369, and 579 or have one or more amino acid mutations that occur at amino acid residues at equivalent positions in the parental RNA polymerase. The mutants are at least improved in terms of any of the following: enzymatic activity, thermal stability, 3' terminal consistency, in-vitro transcription yield, dsRNA byproducts, immunogenicity, and the like, and can meet various requirements of practical application and research.
Need to check novelty before this filing date? Find Prior Art

Description

A mutant RNA polymerase with improved performance Technical Field

[0001] The present invention relates to an RNA polymerase mutant with improved performance, belonging to the technical fields of genetic engineering and enzyme engineering. Background Art

[0002] T7 RNA polymerase (T7 RNAP), derived from the Escherichia coli bacteriophage T7, is a DNA-dependent, single-subunit RNA polymerase that highly specifically recognizes the T7 promoter sequence. This enzyme has a wide range of applications in in vitro RNA synthesis, including the synthesis of guide RNA (gRNA), siRNA, and isotopically or non-isotopically labeled RNA probes. It also synthesizes capped mRNA with the help of a cap analog for intracellular or in vivo expression, as well as for mRNA vaccine and drug research. Furthermore, it can be used in isothermal amplification methods such as sequence-specific nucleic acid in vitro amplification (NASBA) and transcription-mediated amplification (TMA).

[0003] However, wild-type T7 RNAP has some shortcomings in practical applications. For example, the RNA synthesis process may produce byproducts, including short fragments generated during transcription initiation, 3'-terminal extension products, and dsRNA byproducts. These byproducts can affect the effectiveness of mRNA vaccine and drug research. With the development of mRNA drugs and molecular diagnostic technologies, the wild-type T7 RNA polymerase currently on the market cannot fully meet the growing research needs and needs to be optimized and improved to achieve greater application value.

[0004] Several technologies have been developed to improve T7 RNAP, including mutants with enhanced enzymatic activity, mutants that reduce dsRNA contaminants, and mutants with improved thermal stability. For example, US20150024435 A1 provides a T7 RNA polymerase mutant with enhanced enzymatic activity, CN 111212905 A provides a T7 RNAP mutant that reduces dsRNA contaminants and concatenated transcripts produced during in vitro transcription reactions, and CN 112831484 B provides a T7 RNAP mutant suitable for synthesizing RNAs containing internal termination signals and RNAs with hairpin ends, capable of synthesizing Cas9 sgRNAs of higher purity than T7 RNAP-WT. CN 108779446 A and US 9193959 B2 provide T7 RNAP mutants with enhanced thermal stability. However, these existing mutants often face challenges, such as insufficient performance improvement, challenges balancing thermal stability and activity, or ineffective reduction of side products.

[0005] Therefore, the present invention aims to develop a T7 RNAP mutant with improved performance, which has at least any of the following performance improvements: enzyme activity, thermal stability, 3' end consistency, in vitro transcription yield, dsRNA byproducts and immunogenicity, etc., to meet the various needs of practical applications and research.

[0006] Summary of the Invention

[0007] To address the above problems, the present invention provides a series of RNA polymerase mutants with improved performance. These mutants have at least any of the following performance improvements: enzyme activity, thermal stability, 3' end consistency, in vitro transcription yield, dsRNA byproducts, and immunogenicity, etc., which can meet the various needs of practical applications and research.

[0008] A first object of the present invention is to provide an RNA polymerase mutant with improved performance, wherein the RNA polymerase mutant has one or more amino acid mutations at positions 121, 223, 632, 217, 397, 369, and 579, or one or more amino acid mutations at amino acid residues at equivalent positions in the parent RNA polymerase, based on the amino acid sequence corresponding to the parent RNA polymerase; the amino acid sequence of the parent RNA polymerase has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 1 and has RNA polymerase activity;

[0009] In one embodiment, the property is selected from one or more of enzyme activity, thermal stability, 3' end identity, in vitro transcription yield, dsRNA byproducts, and immunogenicity.

[0010] In one embodiment, when the mutation site contains position 121, the amino acid sequence of the parent RNA polymerase has at least 90% identity with the amino acid shown in SEQ ID NO.1 and has RNA polymerase activity; when the mutation site contains position 369, the amino acid sequence of the parent RNA polymerase has at least 98.41% identity with the amino acid shown in SEQ ID NO.1 and has RNA polymerase activity.

[0011] In one embodiment, the parent RNA polymerase is a wild-type T7 RNA polymerase whose amino acid sequence is shown in SEQ ID NO.1.

[0012] In one embodiment, the parent RNA polymerase having at least 80% identity to the amino acid sequence shown in SEQ ID NO. 1 is from a different Escherichia coli phage or other phage, including but not limited to: Escherichia phage T7, Enterobacteria phage vB EcoP IMME390, Enterococcus phage EFA-2, Escherichia phage 13a, Escherichia phage 64795ec1, Escherichia phage ClCC 80001, Escherichia phage Ebrios, Escherichia phage EG1, Escherichia phage HZ2R8, Escherichia phage HZP2, Escherichia phage Jacob Burckhardt, Escherichia phage JeanTinguely, Escherichia phage LL2, Escherichia phage N30, Escherichia phage NC-A, Klebsiella phage Patroon, Salmonella phage 3A_8767, Salmonella phage Vi06, Serratia phage 2050H2, Serratia phage Pila, Serratia phage SlM9-3Y, Escherichia phage JB01, Yersinia phage phiA1122, Yersinia phage vB_YpYeO9, Yersinia phage YpP-R, Aeromonas phage PZL-Ah1, Citrobacter phage SH2, Escherichia phage E-2, Yersinia phage phiYe-F10, Citrobacter phage phiCFP-1, Citrobacter phage SH1, Salmonella phage phiSG-JL2, Yersinia phiYeO3-12, Klebsiella The amino acid sequence of any one of the RNA polymerases selected from Enterobacteria phage 31 and Enterobacteria phage T3. Positions 223, 632, 217, 397, and 579 of the amino acid sequence of the parent RNA polymerase are conserved sequences.

[0013] Alternatively, the accession numbers of the amino acid sequence of the parent RNA polymerase are QZB83517.1, YP 009814072.1, QJT70354.1, YP 002003938.1, YP 009291482.1, YP 009152465.1, YP 009799383.1, YP 009795804.1, YP 009798010.1, YP 009820203.1, QXV80637.1, QXV80862.1, YP 009812318.1, YP 009813771.1, YP 009820155.1, QBQ72872.1, YP 009804754.1, YP 004306655.1, YP 009791749.1, QFG06779.1, YP 009786924.1, QOV06378.1, NP 848264.1, WMX18675.1, AFK13398.1, QMP81608.1, YP_009289300.1, YP_009226209.1, YP_009785350.1, YP_009205657.1, YP_009286631.1, YP_001949750.1, NP_052071.1, QGH73719.1, NP_523301.1, corresponding to SEQ ID NO.1, SEQ ID NOs.29-62, respectively; wherein SEQ ID NOs.29-62 correspond to SEQ ID Compared with the amino acid of NO.1, the amino acids are 97.96%, 98.07%, 98.64%, 98.07%, 98.19%, 90.26%, 97.51%, 97.40%, 97.40%, 98.19%, 98.53%, 82.35%, 98.75%, 97.73%, 82.47%, 98.41%, 92 .98%, 82.47%, 98.41%, 82.47%, 98.30%, 98.41%, 98.19%, 98.53%, 89.92%, 82.69%, 82.58%, 82.47%, 82.47%, 82.35%, 82.47%, 82.24%, 82.13%, 82.01% sequence identity.

[0014] Optionally, the amino acid sequence of the parent RNA polymerase has at least 90% identity with the amino acid shown in SEQ ID NO.1 and has RNA polymerase activity; optionally, the amino acid sequence of the parent RNA polymerase corresponds to SEQ ID NO.1, SEQ ID NO.30-39, SEQ ID NO.41-42, SEQ ID NO.44-45, SEQ ID NO.47, SEQ ID NO.49-53, respectively, and positions 121, 223, 632, 217, 397, and 579 of its amino acid sequence are conserved sequences.

[0015] Optionally, the amino acid sequence of the parent RNA polymerase has at least 98.41% identity with the amino acid shown in SEQ ID NO.1 and has RNA polymerase activity; optionally, the amino acid sequence of the parent RNA polymerase is as shown in SEQ ID NO.1 or SEQ ID NO.44, and the amino acids at positions 121, 223, 632, 217, 397, 369, and 579 in the two sequences are identical.

[0016] In one embodiment, the amino acid at position 217 is mutated to L, A or V, preferably, to L;

[0017] The amino acid at position 397 is mutated to W, A or P, preferably to W;

[0018] The amino acid at position 121 is mutated to M, L or S, preferably to M;

[0019] The amino acid at position 223 is mutated to M, P, L, V or F, preferably, mutated to M;

[0020] The amino acid at position 632 is mutated to G or E, preferably, mutated to G;

[0021] The amino acid at position 369 is mutated to T or E;

[0022] The amino acid at position 579 is mutated to A, W or D; preferably, it is mutated to W.

[0023] In one embodiment, the RNA polymerase mutant further comprises mutations at one or more of the following positions corresponding to the amino acid sequence of the parent RNA polymerase: position 430, position 633, position 786, position 744, position 724, position 43, and position 723.

[0024] In one embodiment, the amino acid at position 430 is mutated to a non-polar hydrophobic amino acid; alternatively, it is mutated to P, L, V, M, or F; preferably, it is mutated to P;

[0025] The amino acid at position 633 is mutated to a non-polar hydrophobic amino acid; optionally, it is mutated to P, L, V, M or F, A, I, W; preferably, it is mutated to P;

[0026] The amino acid at position 786 is mutated to a non-polar hydrophobic amino acid or Y; alternatively, it is mutated to P, I, A, V, Y, L, M, W or F; preferably, it is mutated to L;

[0027] The amino acid at position 744 is mutated to R, P or L; preferably, it is mutated to R;

[0028] The amino acid at position 43 is mutated to Y or A; preferably, it is mutated to Y;

[0029] The amino acid at position 723 is mutated to E or S; preferably, it is mutated to E;

[0030] The amino acid at position 724 is mutated to N.

[0031] In one embodiment, the RNA polymerase mutant comprises at least any one of the following mutations that is equivalent to or corresponds to the parent polymerase mutant: I217L, I217A, I217V, S397W, S397A, S397P, T121M, T121L, T121S, S223M, S223P, S223L, S223V, S223F, R632G, R632E, M369E, M369T, N579A, N579W, N579D mutations.

[0032] In one embodiment, the RNA polymerase mutant simultaneously has at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P and Q786L, and is named I217L / S397W / S430P / S633P / Q786L (hereinafter referred to as M7).

[0033] In one embodiment, the RNA polymerase mutant simultaneously has at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P, Q786L, N579W, and is named I217L / S397W / S430P / S633P / Q786L / N579W.

[0034] In one embodiment, the RNA polymerase mutant simultaneously has at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P, Q786L, Q744R, and is named I217L / S397W / S430P / S633P / Q786L / Q744R.

[0035] In one embodiment, the RNA polymerase mutant simultaneously has at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P, Q786L, C723E, A724N, and is named I217L / S397W / S430P, S633P / Q786L / C723E / A724N.

[0036] In one embodiment, the RNA polymerase mutant simultaneously contains at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P, Q786L, Q744R, and S43Y, and is named I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y (hereinafter referred to as M8).

[0037] In one embodiment, the amino acid sequence of the RNA polymerase mutant is such as SEQ ID NO.2 (corresponding to I217L), SEQ ID NO.3 (corresponding to S397W), SEQ ID NO.4 (corresponding to T121M), SEQ ID NO.5 (corresponding to S223M), SEQ ID NO.6 (corresponding to R632G), SEQ ID NO.7 (corresponding to I217L / S397W / S430P / S633P / Q786L) or SEQ ID NO.8 (corresponding to I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y), SEQ ID NO.79 (corresponding to M369T), SEQ ID NO.80 (corresponding to N579W), SEQ ID NO.81 (corresponding to I217L / S397W / S430P / S633P / Q786L / N579W), SEQ ID NO. NO.82 (corresponding to I217L / S397W / S430P / S633P / Q786L / Q744R) and SEQ ID NO.83 (corresponding to I217L / S397W / S430P / S633P / Q786L / C723E / A724N).

[0038] The second object of the present invention is to provide a polynucleotide encoding the aforementioned RNA polymerase mutant.

[0039] In one embodiment, the sequence of the polynucleotide is as shown in SEQ ID NO.16 (corresponding to I217L), SEQ ID NO.17 (corresponding to S397W), SEQ ID NO.18 (corresponding to T121M), SEQ ID NO.19 (corresponding to S223M), SEQ ID NO.20 (corresponding to R632G), SEQ ID NO.21 (corresponding to I217L / S397W / S430P / S633P / Q786L), and SEQ ID NO.22 (corresponding to I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y).

[0040] The third object of the present invention is to provide a vector carrying the aforementioned polynucleotide.

[0041] Optionally, the vector is pQE-80L, or may be pET-28a(+) or pPIC9K.

[0042] A fourth object of the present invention is to provide a cell carrying the aforementioned polynucleotide or vector, or expressing the aforementioned RNA polymerase mutant. The cell may refer to a single cell, a cell line, or a cell culture. Cells herein include their progeny, which may not necessarily be identical to the original cell due to natural, accidental, or intentional mutations, and may differ from the original cell in morphology and / or genomic DNA. The cell may be a native cell or a transformant.

[0043] A fifth object of the present invention is to provide a method for synthesizing a polynucleotide, wherein the method uses the RNA polymerase mutant of the present invention.

[0044] In one embodiment, the synthesis method comprises using an enzyme system comprising the RNA polymerase mutant to catalyze the synthesis of a polynucleotide or using the whole cell of the above cell to catalyze the synthesis of a polynucleotide.

[0045] Optionally, the synthesis method comprises in vitro transcription synthesis, isothermal amplification or transcription-mediated amplification.

[0046] The sixth object of the present invention is to provide an application of the above-mentioned RNA polymerase mutant or the above-mentioned polynucleotide synthesis method in at least one of mRNA vaccine preparation, nucleic acid drug preparation, gene editing and protein expression system construction, and the protein expression system construction includes but is not limited to in vivo protein expression system construction or cell-free protein expression in vitro translation system construction.

[0047] A seventh object of the present invention is to provide a kit for polynucleotide synthesis, which comprises the aforementioned RNA polymerase mutant.

[0048] An eighth object of the present invention is to provide a method for improving at least one property of an RNA polymerase; the property is selected from the group consisting of improved enzymatic activity, improved thermal stability, improved 3' end identity, higher in vitro transcription yield, fewer dsRNA byproducts, and lower immunogenicity, the method comprising: based on the amino acid sequence corresponding to a parent RNA polymerase, one or more amino acid mutations are present at positions 121, 223, 632, 217, 397, 369, and 579, or one or more amino acid mutations are present at amino acid residues at equivalent positions in the parent RNA polymerase; the amino acid sequence of the parent RNA polymerase has at least 80% identity with the amino acid sequence shown in SEQ ID NO.1 and has RNA polymerase activity.

[0049] In one embodiment, when the mutation site contains position 121, the amino acid sequence of the parent RNA polymerase has at least 90% identity with the amino acid shown in SEQ ID NO.1 and has RNA polymerase activity; when the mutation site contains position 369, the amino acid sequence of the parent RNA polymerase has at least 98.41% identity with the amino acid shown in SEQ ID NO.1 and has RNA polymerase activity.

[0050] Beneficial effects of the present invention:

[0051] The present invention provides a series of RNA polymerase mutants with improved performance, which have at least any of the following performance improvements: enzyme activity, thermal stability, 3' end consistency, dsRNA byproducts and immunogenicity, etc., and can meet various needs of practical applications and research.

[0052] in:

[0053] (1) Based on the RNA polymerase with the amino acid sequence shown in SEQ ID NO. 1, the present invention mutated the amino acid at position 121 to construct single-point mutants T121M, T121A, and T121V. Compared with the wild-type WT, the enzyme activity was increased by more than 47%. Among them, T121M had the highest enzyme activity, which was increased by 123% compared with the wild-type WT.

[0054] By mutating amino acid position 217, single-point mutants I217L, I217A, and I217V were constructed, which increased enzyme activity by more than 47% compared to the wild-type WT. Among them, I217L had the highest enzyme activity, increasing by 34% compared to the wild-type WT.

[0055] By mutating the amino acid at position 223, single-point mutants S223M, S223L, and S223V were constructed, which increased the enzyme activity by more than 18% compared with the wild-type WT. Among them, S223M had the highest enzyme activity, which increased by 25% compared with the wild-type WT.

[0056] By mutating the amino acid at position 397, single-point mutants S397W and S397P were constructed, which increased the enzyme activity by more than 36% compared with the wild-type WT. Among them, S397W had the highest enzyme activity, which increased by 62% compared with the wild-type WT.

[0057] By mutating the amino acid at position 632, single-point mutants R632G and R632E were constructed, which increased the enzyme activity by more than 20% compared with the wild-type WT. Among them, R632G had the highest enzyme activity, which increased by 22% compared with the wild-type WT.

[0058] The single-point mutant N579W was constructed by mutating the amino acid at position 579, and the enzyme activity was increased by 46% compared with the wild-type WT;

[0059] Among them, the relative enzyme activities of the single point mutant I217L, single point mutant S397W, single point mutant T121M, single point mutant S223M and single point mutant R632G at 37°C are significantly better than those of the single point mutant S430P, single point mutant G47A+884G, single point mutant S633P and single point mutant Q786L reported in the prior art.

[0060] (2) The present invention combined mutations based on single-point mutations to construct combined mutants I217L / S397W / S430P / S633P / Q786L (i.e., M7), I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y (i.e., M8), I217L / S397W / S430P / S633P / Q786L / Q744R, and I217L / S397W / S430P / S633P / Q786L / C723E / A724N. Compared with the wild type WT, I217L / S397W / The enzyme activity of S430P / S633P / Q786L / Q744R increased by 95%, the enzyme activity of I217L / S397W / S430P / S633P / Q786L / C723E / A724N increased by 83%, and the enzyme activity of M8 increased by 336%; the Tm values ​​of M7, M8, I217L / S397W / S430P / S633P / Q786L / Q744R and I217L / S397W / S430P / S633P / Q786L / C723E / A724N were significantly higher than those of the wild type and other mutants reported in the prior art.

[0061] (3) The in vitro transcription yield and 3' end consistency product of the combined mutant M8 of the present invention at 50°C are significantly better than those of the wild-type WT and other mutants reported in the prior art, indicating that the combined mutant M8 has a higher IVT yield and 3' end consistency; the IVT yields of I217L / S397W / S430P / S633P / Q786L / Q744R and I217L / S397W / S430P / S633P / Q786L / C723E / A724N at 37°C are increased by 43% and 10.7% respectively compared with the wild-type WT, and the purities reach 79.4% and 77.4%, respectively.

[0062] (4) The content of dsRNA transcription byproducts of the combined mutants M8, I217L / S397W / S430P / S633P / Q786L / Q744R and I217L / S397W / S430P / S633P / Q786L / C723E / A724N of the present invention is significantly lower than that of the wild type WT, the mutants reported in the prior art, and the M7 combined mutant. The dsRNA content per unit mass of IVT product of the M8 combined mutant is low under reaction conditions of 50°C, and can reach the same level as the G47A+884G mutant reported in CN 111212905A, which can reduce dsRNA contaminants and concatenated transcripts in in vitro transcription products.

[0063] (5) The in vitro transcription product of the combined mutant M8 of the present invention has lower immunogenicity than the wild type.

[0064] (6) The present invention successfully established a high-throughput T7 RNAP mutant library screening platform by using the FADS platform to encapsulate single cells and reaction systems. Using this platform, the present invention screened the following T7 RNA polymerase mutants, which correspond to the amino acid sequence shown in SEQ ID NO.1 and have at least one of the following amino acid residues: L at position 217, A or W at position 397, and A or W at position 579; and have at least 80% identity with SEQ ID NO.1. The T7 RNA polymerase mutants provided by the present invention have good thermal stability and a good temperature adaptability range. They can react not only under conventional conditions of 37°C, but also under high temperature conditions of 50°C. The T7 RNAP mutants provided by the present invention also have good application performance under 37°C conditions. The T7 RNA polymerase combination mutants containing multiple mutation sites have a purity of in vitro transcription products that is better than that of wild-type T7 RNA polymerase or reported T7 RNA polymerase mutants. The T7 RNA polymerase mutant provided by the present invention still has very good application performance under 50°C conditions. The yield of synthesized RNA is significantly better than that of the wild type and reported mutants. The product purity is not inferior to that of the existing technology. In addition, the synthesized mRNA has fewer dsRNA byproducts and will produce lower immunogenicity. The 3' consistency of the product is significantly improved compared with the existing technology. These indicators are very beneficial for the research and production of mRNA vaccines and drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the specific embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0066] Figure 1 is a schematic diagram of the T7 RNAP recombinant expression vector;

[0067] FIG2 is a flow chart of microdroplet sorting based on fluorescence activation of aptamers;

[0068] FIG3 is a graph showing the change in protein concentration of the wild-type T7 RNAP as a function of fluorescence intensity when the relative activities of different mutants were determined by real-time fluorescence assay;

[0069] Figure 4A shows the dsRNA content detection results of IVT products of T7 RNAP wild type and single mutants S430P, S633P, Q786L, I217L, S397W, combined mutants I217L / S397W / S430P / S633P / Q786L, I217L / S397W / S430P / S633P / Q786L / N579W, I217L / S397W / S430P / S633P / Q786L / Q744R, and I217L / S397W / S430P / S633P / Q786L / C723E / A724N;

[0070] Figure 4B shows the dsRNA content detection results of IVT products of T7 RNAP wild type and single mutants I217L, S397W, S430P, S633P, Q786L, combination mutant I217L / S397W / S430P / S633P / Q786L, combination mutant I217L / S397W / S430P / S633P / Q786L / N579W, combination mutant I217L / S397W / S430P / S633P / Q786L / Q744R, and combination mutant I217L / S397W / S430P / S633P / Q786L / C723E / A724N;

[0071] Figure 5A shows the 3' end consistency test results of the IVT product of wild-type T7 RNAP at 37°C;

[0072] Figure 5B shows the 3' end consistency test results of the IVT product of T7 RNAP mutant Q744R at 37°C;

[0073] Figure 5C shows the 3' end consistency test results of the IVT product of T7 RNAP mutant S43Y at 37°C;

[0074] Figure 5D shows the 3' end consistency test results of the IVT product of T7 RNAP mutant G47A+884G at 37°C;

[0075] Figure 5E shows the 3' end consistency test results of the IVT product of T7 RNAP mutant M7: I217L / S397W / S430P / S633P / Q786L at 37°C;

[0076] Figure 5F shows the 3' end consistency test results of the IVT product of T7 RNAP mutant M7: I217L / S397W / S430P / S633P / Q786L at 50°C;

[0077] Figure 5G shows the 3' end consistency test results of the IVT product of T7 RNAP mutant M8: I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y at 37°C;

[0078] Figure 5H shows the 3' end consistency test results of the IVT product of T7 RNAP mutant M8: I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y at 50°C;

[0079] Figure 5I shows the 3' end consistency test results of the IVT product of T7 RNAP mutant I217L at 50°C;

[0080] Figure 5J shows the 3' end consistency test results of the IVT product of T7 RNAP mutant S397W at 50°C;

[0081] Figure 6A shows the detection results of IFN-α, a cellular immune response factor, in the IVT products of wild-type T7 RNAP and mutant M8;

[0082] FIG6B shows the detection results of the cellular immune response factor IL-6 produced by the IVT products of T7 RNAP wild type and mutant M8;

[0083] FIG7A is a sequence conservation analysis of T7 RNAP mutation sites 1 to 129 in the amino acid sequences of RNA polymerases from different sources;

[0084] FIG7B is a sequence conservation analysis of T7 RNAP mutation sites 130 to 259 in the amino acid sequences of RNA polymerases from different sources;

[0085] FIG7C is a sequence conservation analysis of T7 RNAP mutation sites 260 to 389 in the amino acid sequences of RNA polymerases from different sources;

[0086] FIG7D is a sequence conservation analysis of T7 RNAP mutation sites 390 to 519 in the amino acid sequences of RNA polymerases from different sources;

[0087] FIG7E is a sequence conservation analysis of T7 RNAP mutation sites 520 to 650 in the amino acid sequences of RNA polymerases from different sources. DETAILED DESCRIPTION

[0088] The following will clearly and completely describe the technical solutions of the present invention in conjunction with the embodiments. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0089] Some definitions or terms related to the present invention:

[0090] Improved performance: The term "improved performance" refers to characteristics associated with a variant that are improved relative to the parental variant. Such improved performance includes, but is not limited to, one or more of the following: improved enzymatic activity of the RNA polymerase mutant, improved thermostability, higher in vitro transcription yields in in vitro transcription (IVT) reactions, improved 3' end identity, reduced dsRNA byproducts, or RNA transcripts produced by the RNA polymerase mutant that are less immunogenic.

[0091] Corresponding to: As used herein, the term "corresponding to" refers to a method of determining a specific amino acid in a sequence where a specific amino acid sequence is referenced. For example, for the purposes of the present invention, when reference is made to a specific amino acid position, a skilled artisan can compare another amino acid sequence with the referenced amino acid sequence to determine which specific amino acid may be of interest in the other amino acid sequence. Alternative alignment methods may be used and are well known to those skilled in the art.

[0092] Mutant: As used herein, the term "mutant" or "polypeptide variant" or "polypeptide" or "RNA polymerase mutant" when used in reference to variants of the present invention means a polypeptide having RNA polymerase enzymatic activity that comprises an alteration (i.e., a substitution, insertion, and / or deletion) at one or more (e.g., several) positions relative to a "parent" RNA polymerase. A substitution means replacing the amino acid occupying a position with a different amino acid; a deletion means removing the amino acid occupying a position; and an insertion means adding an amino acid adjacent to and immediately following the amino acid occupying a position. In describing the variants of the present invention, the nomenclature described below has been adapted for ease of reference. Accepted IUPAC single-letter or three-letter amino acid abbreviations are used. Substitutions: For amino acid substitutions, the following nomenclature is used: original amino acid, position, substituted amino acid. Thus, a substitution of glutamic acid at position 49 with arginine is represented as "E49R." Multiple mutations are separated by a symbol (" / "), for example, "E49R / M358F" represents that glutamic acid (E) and methionine (M) at position 49 and position 358 are replaced by arginine (R) and phenylalanine (F), respectively.

[0093] Parent or parent RNA polymerase: As used herein, the term "parent" RNA polymerase means an RNA polymerase that is altered to produce an RNA polymerase mutant of the present invention. The term also refers to the polypeptide with which the mutant of the present invention is compared. The parent can be a naturally occurring (wild-type) polypeptide, or it can even be a variant thereof prepared by any suitable means. For example, the parent protein can be a variant of a naturally occurring polypeptide that has been modified or altered in terms of amino acid sequence. Thus, the parent RNA polymerase can have one or more (or one or several) amino acid substitutions, deletions, and / or insertions. Thus, the parent RNA polymerase can be a variant of the parent RNA polymerase. The parent can also be an allelic variant, a polypeptide encoded by any one of two or more alternative forms of a gene occupying the same chromosomal locus.

[0094] Wild-type enzyme: The term "wild-type" when referring to an amino acid sequence or a nucleic acid sequence means that the amino acid sequence or nucleic acid sequence is a natural or naturally occurring sequence. As used herein, the term "naturally occurring" refers to any substance (e.g., a protein, amino acid, or nucleic acid sequence) found in nature. In contrast, the term "non-naturally occurring" refers to any substance not found in nature (e.g., recombinant nucleic acid and protein sequences produced in a laboratory, or modifications of a wild-type sequence). When the parent enzyme is not a variant enzyme, the terms "wild-type enzyme" and "parent enzyme" are used interchangeably.

[0095] Sequence identity: The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter "sequence identity".

[0096] For the purposes of the present invention, the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453), as implemented in the Needle program of the EMBOSS software package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (preferably version 5.0.0 or later). The parameters used can be a gap opening penalty of 10, a gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of the "longest identity" labeled Needle (obtained using the -nobrief option) is used as the identity percentage and is calculated as follows:

[0097] (Identical residues x 100) / (Alignment length - Total number of gaps in the alignment)

[0098] Alternatively, the parameters used can be a gap opening penalty of 10, a gap extension penalty of 0.5, and an EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. Use the output of the "longest identity" labeled by Needle (obtained using the -nobrief option) as percent identity and calculate as follows:

[0099] (number of identical deoxyribonucleotides × 100) / (length of alignment – ​​total number of gaps in the alignment)

[0100] Expression: As used herein, the term "expression" refers to any step involved in the production of a variant including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0101] Expression vector: As used herein, the term "expression vector" refers to a linear or circular DNA molecule that comprises a polynucleotide encoding a variant and is operably linked to control sequences that provide for its expression.

[0102] Host cell: The term "host cell" means any cell type that is susceptible to transformation, transfection, transduction, etc. with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication, as well as recombinant host cells, isolated host cells (e.g., isolated recombinant host cells), and heterologous host cells.

[0103] Recombinant: When used in reference to a cell, nucleic acid, protein, or vector, the term "recombinant" means that it has been modified from its native state. Thus, for example, a recombinant cell expresses genes not found in the native (non-recombinant) form of the cell, or expresses native genes at different levels or under different conditions than they are found in nature. A recombinant nucleic acid differs from a native sequence by one or more nucleotides and / or is operably linked to a heterologous sequence (e.g., a heterologous promoter in an expression vector). A recombinant protein may differ from a native sequence by one or more amino acids and / or be fused to a heterologous sequence. A vector comprising a nucleic acid encoding a polypeptide is a recombinant vector. The term "recombinant" is synonymous with "genetically modified" and "transgenic."

[0104] The following will clearly and completely describe the technical solutions of the present invention in conjunction with the embodiments. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0105] It should be noted that the abbreviations for amino acid residues herein are generally defined in the art. In some instances, the full name is indicated in parentheses after the abbreviation. "Amino acid residue" and "amino acid" are used interchangeably herein. Amino acid sequences herein are sequenced starting from the nitrogen terminus.

[0106] In some optional embodiments, a method for screening T7 RNA polymerase mutants is provided, comprising amplifying a polynucleotide encoding T7 RNA polymerase in a reaction system containing manganese ions, then transforming a vector carrying the amplified product into cells, inducing expression, and sorting target cells using a droplet microfluidic cell sorting method; the manganese ion concentration in the reaction system is 0.1-0.6 mM, preferably 0.2 mM-0.3 mM. Droplet microfluidic cell sorting is based on the microfluidic ultra-high-throughput Fluorescence-Activated Droplet Sorting (FADS) platform. The FADS screening process includes three steps: droplet encapsulation and incubation of single cells, incubation and reaction, and ultra-high-throughput screening of single-cell droplets after the reaction. FADS can encapsulate and culture single cells, use specific fluorescent substrates to quantify the production of secondary metabolites or specific enzymes of single cells, and use the screening platform to sort and collect droplets whose fluorescence intensity meets the screening threshold, ultimately obtaining a large number of candidate droplets. This screening method has the advantages of high throughput and strong specificity.

[0107] In an optional embodiment, the heat treatment condition is 40-50°C for 5-10 min, preferably 45°C for 7 min.

[0108] In an alternative embodiment, the target cells are the 0.4% to 0.45% of droplet-encapsulated cells that exhibit the highest viability.

[0109] In an optional embodiment, the amplified polynucleotide encoding T7 RNA polymerase has a nucleotide sequence as shown in SEQ ID NO.15, which expresses a wild-type T7 RNA polymerase having an amino acid sequence as shown in SEQ ID NO.1.

[0110] In an optional embodiment, the method further comprises at least one step of isolating target fragments from target cells sorted by a droplet microfluidic cell sorting method, transforming the fragments into another cell, and culturing the cells and then screening the cells again.

[0111] In an optional embodiment, the T7 RNA polymerase mutants expressed in positive cells are collected, the system containing the T7 RNA polymerase mutants is heat-treated, and then the enzyme activity is determined, and the positive clones with an enzyme activity of at least 1.5 times that of the wild type are sequenced.

[0112] In one embodiment, T7 RNA polymerase mutants were screened using the following protocol:

[0113] First, the T7 RNAP gene (SEQ ID NO. 15) was amplified by PCR using the recombinant vector pQE-80L-T7 RNAP containing the wild-type T7 RNAP gene as a template. 2+ The concentration was used to obtain amplification products with different mutation degrees; the products were then connected to the vector pQE-80L to construct a recombinant expression vector, which was electroporated into competent E. coli 10G. Based on the clones grown, the library capacity was calculated to be more than 106, and the Mn with a mutation frequency of 2 to 3 bases per gene was selected. 2+ The concentration is 0.2mM-0.3mM.

[0114] The resulting mixed plasmid mutant library was then electroporated into fresh competent E. coli BL21 (DE3) cells, yielding a mutant library containing approximately 107 clones. Following the protein expression procedures, E. coli was induced and expressed, and the FADS platform was used to encapsulate the single cells and reaction system. The single-cell encapsulation rate was controlled at approximately 10% to improve screening accuracy. During in vitro incubation, the droplets were heated at approximately 45°C for an appropriate time, reducing activity to approximately one-third of its original level to achieve the desired effect of high-temperature treatment. The cells were then incubated at 37°C for 3 hours.

[0115] Before sorting the mutant library using FADS, the optimal laser spot position, sorting speed, and other conditions were determined by sorting FITC and ink. The incubated microdroplets were then injected into a detection and sorting chip. Approximately 0.42% of droplets exhibiting the highest activity were collected in a 1.5 mL centrifuge tube. Positive genes were recovered by PCR, and the target fragments were digested with BamHI and HindIII and reconstructed into the pQE-80L linearized vector. The ligated vector was then transformed into BL21(DE3) competent cells, and single colonies growing on the plates were selected for rescreening.

[0116] During the sorting process, several rounds of sorting were performed on different batches of transformed mutant libraries, and the resulting positive genes were pooled and recovered to ensure that more beneficial mutations were sorted. Fresh single clones were selected from the clones obtained in the previous round and plated in a 96-well plate, with a wild-type BL21(DE3)-T7 RNAP single clone used as a control. After induction and expression, crude enzyme solution was prepared using cell lysis buffer. The crude enzyme solution was heat-treated at 45°C for 5 minutes, quickly placed on ice, and then transferred to a 384-well plate. Enzyme activity was measured using the STAR system (iSpinach aptamer-based monitoring of transcription activity in real-time (STAR) system, see Chinese patent application number CN202211274914.8, entitled "A method for real-time monitoring of in vitro transcribed RNA"; for a detailed description and method of use of this system, see CN115896213A). Then, the mutants whose residual activity after heat treatment was at least 1.5 times that of the wild type were sequenced, and the distribution of mutation points was analyzed based on the sequencing results.

[0117] Based on the distribution of the aforementioned mutation points, recombinant expression vectors carrying nucleotide sequences encoding T7 RNAP mutants were constructed and transformed into BL21(DE3) competent Escherichia coli cells to obtain recombinant strains of wild-type and mutant T7 RNAP. Expression was induced and the T7 RNAP mutants were prepared by protein purification. Subsequently, single-stranded RNA aptamers were synthesized via in vitro transcription. These single-stranded RNAs bind to the specific small molecule DFHBI, resulting in a significant fluorescence signal enhancement. The relative activity of the different mutants compared to T7 RNAP-WT was determined by monitoring the changes in fluorescence during the reaction. Furthermore, the Tm values ​​of the different mutants were determined by binding the T7 RNAP mutant protein solutions to Sypro Orange dye using differential scanning fluorimetry. The performance of the T7 RNAP mutants was assessed by analyzing the in vitro transcription (IVT) products, including IVT yield, product purity, dsRNA content, and 3' end identity.

[0118] In the above embodiment, multiple mutation sites that can improve the thermostability of T7 RNA polymerase mutants were screened. Therefore, the present invention also provides T7 RNA polymerase mutants screened by the above screening process. The T7 RNA polymerase mutants described herein are polypeptides that differ from wild-type T7 RNA polymerase by at least one amino acid residue. In an alternative embodiment, the amino acid sequence of the wild-type T7 RNA polymerase is shown in SEQ ID NO. 1.

[0119] The T7 RNA polymerase mutant provided by the present invention contains at least one of the following amino acid residues: L (leucine) at position 217, A (alanine) or W (tryptophan) at position 397, and A (alanine) or W (tryptophan) at position 579, corresponding to the amino acid sequence set forth in SEQ ID NO. 1. The T7 RNA polymerase mutant containing the aforementioned amino acid residues exhibits excellent thermal stability.

[0120] The term "corresponding to the amino acid sequence set forth in SEQ ID NO. 1" as used herein refers to amino acid residues identified by their position numbers in the amino acid sequence set forth in SEQ ID NO. 1 when the T7 RNA polymerase mutant is aligned with the amino acid sequence set forth in SEQ ID NO. 1. For example, when one or more amino acid residues are missing from the nitrogen-terminus of the T7 RNA polymerase mutant, the position number of an amino acid residue in the amino acid sequence set forth in SEQ ID NO. 1 in the T7 RNA polymerase mutant will differ from the position number in the T7 RNA polymerase mutant. For example, when N amino acid residues are missing from the nitrogen-terminus of the T7 RNA polymerase mutant, an amino acid residue that is at position i in the amino acid sequence set forth in SEQ ID NO. 1 will be at position iN in the amino acid sequence of the T7 RNA polymerase mutant. Amino acid residues are defined herein by their position in the amino acid sequence set forth in SEQ ID NO. 1, rather than by their position in the mutant.

[0121] Furthermore, the T7 RNA polymerase mutants provided herein are at least 80% identical to SEQ ID NO. 1, for example, but not limited to, at least 80%, 85%, 90%, or 95% identical to SEQ ID NO. 1. As used herein, "identity" or similar terms refer to the percentage of identical nucleotides or amino acids between the compared sequences when optimally aligned. This percentage is purely statistical, and the differences between the two sequences may (but are not necessarily) randomly distributed over the entire length of the compared sequences. Comparison of two sequences is typically performed by identifying local regions of corresponding sequences relative to a segment or "comparison window" after optimal alignment.

[0122] It is understood that a T7 RNA polymerase mutant having at least 80% identity to SEQ ID NO. 1 contains at least one of the amino acid residues at position 217 being L, at position 397 being A or W, and at position 579 being A or W.

[0123] In an optional embodiment, the T7 RNA polymerase mutant contains an amino acid residue corresponding to position 217 of the amino acid sequence shown in SEQ ID NO.1, which is L, and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.

[0124] In an optional embodiment, the T7 RNA polymerase mutant contains an amino acid residue corresponding to position 397 of the amino acid sequence shown in SEQ ID NO.1, which is A or W, and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1, wherein position 397 is preferably W.

[0125] In an optional embodiment, the T7 RNA polymerase mutant contains an amino acid residue corresponding to position 579 of the amino acid sequence shown in SEQ ID NO.1, which is A or W, and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1, wherein position 579 is preferably W.

[0126] In an optional embodiment, the T7 RNA polymerase mutant removes at least one of the aforementioned amino acid residues and further includes at least one of the following: corresponding to the amino acid sequence shown in SEQ ID NO.1, at least one of positions 369, 430, 633, 786, 744, 723 and 724 is different from SEQ ID NO.1.

[0127] In an alternative embodiment, position 633 corresponding to the amino acid sequence of SEQ ID NO. 1 is a non-polar, hydrophobic amino acid, more preferably P (proline), L (leucine), V (valine), M (methionine), or F (phenylalanine); even more preferably P, and having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO. 1. Mutation at position 633 may improve the stability of T7 RNA polymerase.

[0128] In an alternative embodiment, position 744 corresponding to the amino acid sequence of SEQ ID NO. 1 is R (arginine), P (proline), or L (leucine); more preferably R; and the residue is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO. 1. Mutation at position 744 is beneficial for enhancing T7 RNA polymerase activity.

[0129] In an alternative embodiment, position 786 corresponding to the amino acid sequence of SEQ ID NO. 1 is Y (tyrosine) or a non-polar, hydrophobic amino acid; more preferably Y, L (leucine), M (methionine), W (tryptophan), or F (phenylalanine); and even more preferably L; and the residue is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO. 1. Mutation at position 786 may improve the stability of T7 RNA polymerase.

[0130] In an alternative embodiment, position 723 corresponding to the amino acid sequence of SEQ ID NO. 1 is E (glutamic acid) or S (serine), more preferably E, and is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO. 1. Mutation at position 723 is beneficial for improving protein aggregation.

[0131] In an optional embodiment, position 369 corresponding to the amino acid sequence shown in SEQ ID NO.1 is T (threonine) or E (glutamic acid); and it has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.

[0132] In an optional embodiment, position 579 corresponding to the amino acid sequence shown in SEQ ID NO.1 is W (tryptophan) or A (alanine); more preferably W; and it has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.

[0133] In an optional embodiment, position 430 corresponding to the amino acid sequence shown in SEQ ID NO.1 is P (proline); and it has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.

[0134] In an optional embodiment, the 724th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is N (asparagine); and it has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.

[0135] In an optional embodiment, the T7 RNA polymerase mutant is selected from any one of the following:

[0136] (a) There is at least an I217L mutation in the amino acid sequence shown in SEQ ID NO. 1; that is, position 217 of SEQ ID NO. 1 is mutated from isoleucine to leucine.

[0137] (b) There is at least an S397W mutation in the amino acid sequence shown in SEQ ID NO. 1; that is, position 397 of SEQ ID NO. 1 is mutated from serine to tryptophan.

[0138] (c) There is at least an N579W mutation in the amino acid sequence shown in SEQ ID NO. 1; that is, position 579 of SEQ ID NO. 1 is mutated from asparagine to tryptophan.

[0139] (d) at least I217L, S397W, S430P, S633P and Q786L mutations exist in the amino acid sequence shown in SEQ ID NO.1; that is, position 217 of SEQ ID NO.1 is mutated from isoleucine to leucine, position 397 is mutated from serine to tryptophan, position 430 is mutated from serine to proline, position 633 is mutated from serine to proline, and position 786 of glutamine is mutated from leucine.

[0140] (e) at least I217L, S397W, S430P, S633P, Q786L and N579W mutations exist in the amino acid sequence of SEQ ID NO.1; that is, position 217 of SEQ ID NO.1 is mutated from isoleucine to leucine, position 397 is mutated from serine to tryptophan, position 430 is mutated from serine to proline, position 633 is mutated from serine to proline, position 786 is mutated from glutamine to leucine, and position 579 is mutated from asparagine to tryptophan.

[0141] (f) at least I217L, S397W, S430P, S633P, Q786L and Q744R mutations exist in the amino acid sequence shown in SEQ ID NO.1; that is, position 217 of SEQ ID NO.1 is mutated from isoleucine to leucine, position 397 is mutated from serine to tryptophan, position 430 is mutated from serine to proline, position 633 is mutated from serine to proline, position 786 is mutated from glutamine to leucine, and position 744 is mutated from glutamine to arginine.

[0142] (g) at least I217L, S397W, S430P, S633P, Q786L, C723E, and A724N mutations are present in the amino acid sequence of SEQ ID NO. 1. That is, position 217 of SEQ ID NO. 1 is mutated from isoleucine to leucine, position 397 is mutated from serine to tryptophan, position 430 is mutated from serine to proline, position 633 is mutated from serine to proline, position 786 is mutated from glutamine to leucine, position 723 is mutated from cysteine ​​to glutamic acid, and position 724 is mutated from alanine to asparagine.

[0143] In an optional embodiment, the amino acid sequence of the T7 RNA polymerase mutant is shown in SEQ ID NO.2 (corresponding to I217L), SEQ ID NO.3 (corresponding to S397W), SEQ ID NO.4 (corresponding to T121M), SEQ ID NO.5 (corresponding to S223M), SEQ ID NO.6 (corresponding to R632G), SEQ ID NO.7 (corresponding to I217L / S397W / S430P / S633P / Q786L) or SEQ ID NO.8 (corresponding to I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y), SEQ ID NO.79 (corresponding to M369T), SEQ ID NO.80 (corresponding to N579W), SEQ ID NO.81 (corresponding to I217L / S397W / S430P / S633P / Q786L / N579W), SEQ ID NO. NO.82 (corresponding to I217L / S397W / S430P / S633P / Q786L / Q744R) and SEQ ID NO.83 (corresponding to I217L / S397W / S430P / S633P / Q786L / C723E / A724N).

[0144] SEQ ID NO. 2 is a T7 RNA polymerase mutant with a single point mutation I217L, with a Tm value of 50.5±0.21°C and a residual activity of 52% after treatment at 50°C for 5 minutes. Taking the wild-type enzyme activity as 100% as a reference, the activity of this mutant is 134%.

[0145] SEQ ID NO. 3 is a T7 RNA polymerase mutant with a single point mutation S397W, with a Tm value of 49.2±0.13°C and a residual activity of 47% after treatment at 50°C for 5 minutes. Taking the wild-type enzyme activity as 100% as a reference, the activity of this mutant is 162%.

[0146] SEQ ID NO. 80 is a T7 RNA polymerase mutant with a single point mutation N579W, a Tm value of which is 48.0±0.23° C., and a residual activity of 38% after treatment at 50° C. for 5 minutes.

[0147] SEQ ID NO.7 is a T7 RNA polymerase mutant with combined mutations I217L, S397W, S430P, S633P, and Q786L, with a Tm value of 54.52±0.20°C and a residual activity of 58% after heat treatment at 58°C for 15 minutes.

[0148] SEQ ID NO.81 is a T7 RNA polymerase mutant with combined mutations I217L, S397W, S430P, S633P, Q786L, and N579W, with a Tm value of 55.56±0.16°C and a residual activity of 65% after heat treatment at 58°C for 15 minutes.

[0149] SEQ ID NO.82 is a T7 RNA polymerase mutant with the combined mutations I217L, S397W, S430P, S633P, Q786L, and Q744R. The Tm value is 54.50±0.18°C, and the residual activity after heat treatment at 58°C for 15 minutes is 87%. Taking the enzyme activity of the wild type as 100% as a reference, the activity of this mutant is 195%.

[0150] SEQ ID NO.83 is a polymerase mutant with combined mutations I217L, S397W, S430P, S633P, Q786L, C723E, and A724N. The Tm value is 54.54±0.23°C, and the residual activity after heat treatment at 58°C for 15 minutes is 81%. Taking the enzyme activity of the wild type as 100% as a reference, the activity of this mutant is 183%.

[0151] According to another aspect of the present invention, the present invention also provides a polynucleotide encoding the above-mentioned T7 RNA polymerase mutant.

[0152] As used herein, "polynucleotide" refers to a polymeric form of nucleotides of any length, including ribonucleotides and / or deoxyribonucleotides. Examples of polynucleotides include, but are not limited to, single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derived nucleotide bases. The polynucleotides encode the T7 RNA polymerase mutants described above, optionally encoding either the sense strand or the antisense strand. The polynucleotides may be naturally occurring, synthetic, recombinant, or any combination thereof. The terms "polynucleotide" and "nucleic acid" are used interchangeably herein.

[0153] According to another aspect of the present invention, the present invention also provides a vector carrying a polynucleotide encoding the above-mentioned T7 RNA polymerase mutant. The vector is well known to those skilled in the art, and includes but is not limited to: a plasmid; a phagemid; a cosmid; an artificial chromosome, such as a yeast artificial chromosome (YAC), a bacterial artificial chromosome (BAC) or a P1-derived artificial chromosome (PAC); a bacteriophage such as lambda phage or M13 phage and an animal virus, etc. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomaviruses. In some embodiments, the vector of the present invention contains regulatory elements commonly used in genetic engineering, such as enhancers, promoters, internal ribosome entry sites (IRES) and other expression control elements (such as transcription termination signals, or polyadenylation signals and poly-U sequences, etc.).

[0154] According to another aspect of the present invention, the present invention further provides a cell carrying the aforementioned polynucleotide or the aforementioned vector, or expressing the aforementioned T7 RNA polymerase mutant. The cell may refer to a single cell, a cell line, or a cell culture. Cells herein include their progeny, which may not necessarily be identical to the original cell due to natural, accidental, or intentional mutations and may differ from the original cell in morphology and / or genomic DNA. The cell may be a native cell or a transformant.

[0155] According to another aspect of the present invention, the present invention also provides a method for synthesizing a polynucleotide, wherein the method uses the RNA polymerase mutant of the present invention. The method for synthesizing the polynucleotide comprises catalyzing a synthesis reaction using an enzyme system comprising the aforementioned T7 RNA polymerase mutant. The synthesis method comprises in vitro transcription synthesis (IVT), isothermal amplification, such as sequence-specific nucleic acid in vitro amplification (NASBA), or transcription-mediated amplification (TMA).

[0156] According to another aspect of the present invention, the present invention also provides the use of the aforementioned T7 RNA polymerase mutant or the aforementioned polynucleotide synthesis method in any one of the following: at least one of mRNA vaccine preparation, nucleic acid drug preparation, gene editing and protein expression system construction, and protein expression system construction includes but is not limited to in vivo protein expression system construction or cell-free protein expression in vitro translation system construction.

[0157] According to another aspect of the present invention, the present invention also provides a kit for polynucleotide synthesis, which comprises the aforementioned T7 RNA polymerase mutant. It is understandable that the kit for polynucleotide synthesis provided by the present invention may also include other detection reagents or consumables acceptable in the art, and those skilled in the art can select corresponding reagents and / or consumables based on the contents well known in the art, such as various general and more specific teaching materials, references, process manuals, product descriptions, standard documents and equipment manuals. Specific optional reagents and consumables in the kit include, but are not limited to, one or more of buffers, salts, metal ions, dNTPs, enzymes, primers, probes, fluorescent dyes, luminescent substrates, reference substances, quality control substances and calibrators.

[0158] The present invention is further described below by way of specific examples. However, it should be understood that these examples are merely provided for more detailed description and are not to be construed as limiting the present invention in any form.

[0159] The following describes the preferred embodiments of the present invention.

[0160] The examples are for better explanation of the present invention and are not intended to limit the present invention.

[0161] Example 1: Construction and screening of mutation library

[0162] 1. Construction of mutation library

[0163] The wild-type T7 RNA polymerase gene nucleotide sequence (corresponding amino acid sequence is shown in SEQ ID NO.1) was optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.15, and then the optimized nucleotide sequence was inserted between the BamHI and HindIII restriction endonuclease sites of the vector pQE-80L (Qiagen, catalog number HG-VYQ0254), thus obtaining the recombinant vector pQE-80L-T7 RNAP containing the wild-type T7 RNAP gene. The plasmid structure is shown in FIG1 . The T7 RNAP gene was amplified using the recombinant vector pQE-80L-T7 RNAP as a template. The degree of mutation was mainly determined by changing the Mn in the reaction system. 2+ The concentration was set to 0.1mM, 0.2mM, 0.3mM, 0.4mM, 0.5mM, 0.6mM Mn 2+ Gene amplification was performed using a concentration gradient, and the optimal mutation rate was 1 to 3 mutation points per gene.

[0164] The amplification system is as follows: pQE-80L-T7 RNAP plasmid (0.2-1 ng / μL), dATP (0.25 mM), dGTP (0.25 mM), dCTP (1.05 mM), dTTP (1.05 mM), DreamTaq Buffer (Takara), DreamTaq (Takara, 0.1 U / μL), MnCl2 (0.1 mM-0.6 mM), T7 RNAP-F (0.2 μM), T7 RNAP-R (0.2 μM), the total PCR reaction system is 50 μL.

[0165] The DNA sequences of the amplification primers T7 RNAP-F and T7 RNAP-R are shown in Table 1, and the amplification PCR program is shown in Table 2:

[0166] Table 1 Amplification primer sequences for mutant library construction

[0167] Table 2 PCR amplification program

[0168] The target fragment size was analyzed by agarose gel electrophoresis, recovered with a kit, and then double-digested with BamHI and HindIII. The digested product was then purified and recovered, and ligated with the linearized pQE-80L vector (double-digested with BamHI and HindIII) overnight under the action of T4 DNA ligase.

[0169] The recovered ligation products were electroporated into electroporation competent E. coli 10G. The library capacity was calculated based on the clones grown. The library capacity was 10 6 Above. At 0.2 mM Mn 2+ The frequency of introduction of mutations was 1.7 bases / gene under 0.3 mM Mn 2+ Under these conditions, the frequency of introduction of mutations is 3.5 bases / gene. Therefore, in this example, 0.2 mM Mn 2+ and 0.3 mM Mn 2+ The mutant plasmids obtained under the above conditions were mixed to obtain a mutant library in which an average of 2.6 mutant bases were introduced into each gene.

[0170] 2. Screening of mutant library

[0171] The mixed plasmid mutant library was electroporated into fresh E. coli BL21 (DE3) competent cells to obtain 10 7The entire screening process is shown in Figure 2. Following the protein expression steps, E. coli is induced and expressed, and the single cell and reaction system are encapsulated using the FADS platform (Fluorescence-Activated Droplet Sorting, FADS) (droplet microfluidic cell sorting based on a microfluidic ultra-high throughput fluorescence-activated droplet sorting platform). The reaction system, as disclosed in patent CN 115896213 A, contains a single clone, 40-100nM DNA template ispinach, 100μM DFHBI, 0.5-6mM NTPs, 30mM MgCl2, 5Mm NaCl, 20mM DTT, 0.002U / μL inorganic pyrophosphatase, and 0.2U / μL mouse ribonuclease inhibitor. The single cell encapsulation rate is controlled at around 10% to improve screening accuracy. During in vitro incubation, the droplets are heat-treated at 45°C for 7 minutes, reducing their activity to approximately one-third of their original level, achieving the desired effect. They are then incubated at 37°C for another 3 hours. Before sorting the mutant library using FADS, the optimal laser spot position, sorting speed, and other conditions are determined by sorting FITC and ink. The incubated droplets are then reinjected into the detection and sorting chip.

[0172] Based on the signal distribution of the mutant library, we set the PMT to 0.43V, the minimum and maximum sorting thresholds to 0.2V and 0.6V, respectively, and the sorting voltage to 1.6V. Approximately 0.42% of droplets exhibiting the highest activity were collected in a 1.5mL centrifuge tube. Positive genes were recovered by PCR, and the target fragments were double-digested with SacI and HindIII and reconstructed into the pQE-80L linearized vector. The ligated vector was again transformed into BL21(DE3) competent cells, and single colonies that emerged on the plates were picked for rescreening. During the actual sorting process, we performed several rounds of sorting on different batches of the transformed mutant library, pooling and recovering the positive genes to ensure that more beneficial mutations were sorted.

[0173] Approximately 393 fresh single clones were selected from the clones obtained in the previous round and plated in a 96-well plate. Three wild-type BL21(DE3)-T7 RNAP single clones were used as controls. After induction and expression, crude enzyme solution was prepared using cell lysis buffer. The crude enzyme solution was heat-treated at 45°C for 5 minutes, immediately placed on ice, and then transferred to a 384-well plate. Enzyme activity was measured using the STAR system (iSpinach aptamer-based monitoring of transcription activity in real-time (STAR), see Chinese patent application number CN202211274914.8, entitled "A method for real-time monitoring of in vitro transcribed RNA"; for details on the system and its use, see CN115896213A). Mutants with residual activity at least 1.5 times that of wild-type after heat treatment were sequenced. Analysis of the sequencing results revealed that the frequencies of mutations at positions 217, 397, 121, 223, 632, 369, and 579 corresponding to the parental RNA polymerase (i.e., wild-type T7 RNAP, amino acid sequence shown in SEQ ID NO. 1) were relatively high.

[0174] Example 2: Preparation of T7 RNAP

[0175] 1. Construction of recombinant vector expressing T7 RNA polymerase mutant

[0176] According to the results obtained in Example 1, the wild-type T7 RNAP shown in the amino acid sequence of SEQ ID NO. 1 was determined as the parent, and amino acid positions 217, 397, 121, 223, and 632 of the parent amino acid sequence were used as key sites to design mutants and combination mutants with amino acid sequences as shown in SEQ ID NOs. 2 to 8; mutants S430P, S633P, Q786L, Q744R, S43Y, and mutant combinations thereof reported in the prior art were designed as controls, and the amino acid sequences were shown in SEQ ID NOs. 9 to 14, namely, the following mutants:

[0177] Single point mutant I217L (SEQ ID NO. 2);

[0178] Single point mutant S397W (SEQ ID NO. 3);

[0179] Single point mutant T121M (SEQ ID NO. 4);

[0180] Single point mutant S223M (SEQ ID NO. 5);

[0181] Single point mutant R632G (SEQ ID NO. 6);

[0182] Combined mutant I217L / S397W / S430P / S633P / Q786L (SEQ ID NO. 7);

[0183] Combined mutant I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y (SEQ ID NO. 8);

[0184] Single point mutant S430P (SEQ ID NO. 9);

[0185] Single point mutant S633P (SEQ ID NO. 10);

[0186] Single point mutant Q786L (SEQ ID NO. 11);

[0187] Single point mutant Q744R (SEQ ID NO. 12);

[0188] Single point mutant S43Y (SEQ ID NO. 13);

[0189] Single point mutant G47A+884G (SEQ ID NO. 14);

[0190] Single point mutant M369T (SEQ ID NO. 79);

[0191] Single point mutant N579W (SEQ ID NO. 80);

[0192] Combined mutant I217L / S397W / S430P / S633P / Q786L / N579W (SEQ ID NO. 81);

[0193] Combined mutant I217L / S397W / S430P / S633P / Q786L / Q744R (SEQ ID NO. 82);

[0194] Combination mutant I217L / S397W / S430P / S633P / Q786L / C723E / A724N (SEQ ID NO. 83).

[0195] Among them, S430P (US7507567B2), S633P (US7507567B2) and Q786L (CN102177236B) are mutation points reported in the prior art to improve the thermal stability of T7 RNAP, Q744R (US20150024435A1) is a mutation point reported in the prior art to improve the activity of T7 RNAP, S43Y (CN112831484B) is a mutation point reported in the prior art to reduce the RdRp activity of T7 RNAP, G47A+884G refers to the addition of an additional amino acid G to the C-terminus of the mutant amino acid sequence on the basis of G47A (full length 883), so that the full length of the mutant is 884. This mutation method (CN111212905A) can reduce dsRNA contaminants and contiguous transcripts produced during the in vitro transcription reaction.

[0196] The specific steps for constructing the mutant vector are as follows: the above amino acid sequences (SEQ ID NOs. 1 to 14, SEQ ID NOs. 79 to 83) were reverse transcribed and optimized according to the Escherichia coli codon to obtain nucleotide sequences (SEQ ID NOs. 15 to 28, SEQ ID NOs. 84 to 88); the nucleotide sequences were then inserted between the BamHI and HindIII restriction endonuclease sites of the vector pQE-80L to form recombinant expression vectors for wild-type T7 RNAP and mutant T7 RNAP.

[0197] 2. Construction of recombinant microbial cells expressing T7 RNA polymerase mutants

[0198] The recombinant expression vector constructed in the previous step was transformed into BL21 (DE3) competent Escherichia coli cells to obtain recombinant strains of T7 RNAP wild type and mutants, which were named as: T7 RNAP-WT (for expressing wild type T7 RNAP), T7 RNAP-I217L (for expressing single point mutant I217L), T7 RNAP-S397W (for expressing single point mutant S397W), 7 RNAP-T121M (for expressing mutant T121M), T7 RNAP-S223M (for expressing mutant S223M), T7 RNAP-R632G (for expressing mutant R632G), T7 RNAP-I217L / S397W / S430P / S633P / Q786L (for expressing combined mutant M7: I217L / S397W / S430P / S633P / Q786L), T7 RNAP-I217L / S397W / S430P / S633P / Q786L, T7 RNAP-I217L / S397W / S430P / S633P / Q786L, T7 RNAP-I217L / S397W / S430P / S633P / Q786L, T7 RNAP-I217L / S397W / S430P / S633P / Q786L, T7 RNAP-I217L / S397W / S430P / S633P / Q786L, T7 RNAP-I217L RNAP-I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y (used to express the combined mutant M8: I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y), and the control recombinant bacteria T7 RNAP-S430P (used to express the single point mutant S430P), T7 RNAP-S633P (used to express the single point mutant S633P), T7 RNAP-Q786L (used to express the single point mutant Q786L), T7 RNAP-G47A+884G (used to express the mutant G47A+884G), T7 RNAP-M369T (used to express the single point mutant M369T), T7 RNAP-N579W (used to express the single point mutant N579W), and T7 RNAP-I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y. RNAP-I217L / S397W / S430P / S633P / Q786L / N579W (for expressing the combined mutant I217L / S397W / S430P / S633P / Q786L / N579W), T7 RNAP-I217L / S397W / S430P / S633P / Q786L / Q744R was used to express the combined mutant (I217L / S397W / S430P / S633P / Q786L / Q744R), I217L / S397W / S430P / S633P / Q786L / C723E / A724N (used to express the combined mutant I217L / S397W / S430P / S633P / Q786L / C723E / A724N).

[0199] 3. Preparation of T7 RNAP

[0200] The wild-type and mutant recombinant strains prepared in the previous step were placed in LB medium containing ampicillin resistance and cultured in a shaking incubator at 37°C until the OD600 value was close to 1.2. Isopropyl-β-D-thiogalactopyranoside (IPTG) was then added to a final concentration of 1 mM and induced expression overnight (16 hours) in a shaking incubator at 25°C. The bacterial pellet was then collected by centrifugation at 5000 rpm for 20 minutes at 4°C. The cells were then fully resuspended in a lysis buffer containing 300 mM NaCl, 20 mM Tris HCl (pH 7.5), 0.5 mg / mL lysozyme, and 0.5 mM DTT and lysed using a homogenizer. The protein lysate was centrifuged in a high-speed refrigerated centrifuge at 18000 rpm for 1 hour at 4°C. The supernatant was then separated and filtered to remove impurities. The filtered supernatant can be temporarily stored on ice for subsequent nickel column purification. Before the protein passes through the nickel column, it is necessary to equilibrate the nickel column with 10 times the volume of elution buffer (20mM Tris HCl (PH7.5), 300mM NaCl, 0.5mM DTT). Then, the previously filtered protein solution is added to the nickel column. After all the protein solution has passed through the nickel column filler, it is first washed with a certain concentration of Triton, and then eluted with different gradients of imidazole solution (50mM 100mM 150mM-200mM-500mM). Several test tubes are numbered in order of outflow and the outflow is collected. All the above operations must be performed on ice or at 4°C. Then, all eluted protein outflow is detected by SDS-PAGE electrophoresis and Coomassie Brilliant Blue staining. Finally, the protein collection solution with higher concentration and better purity was comprehensively selected for ultrafiltration and centrifugation, and the protein was replaced into enzyme storage buffer for storage. The enzyme storage buffer composition was 50mM Tris-HCl, 100mM NaCl, 20mM 2-Mercaptoethanol, 1mM EDTA, 50% Glycerol, 0.1% Triton X-100, pH 7.9.

[0201] Example 3: Real-time fluorescence assay for enzyme activity of different mutants

[0202] The wild-type T7 RNA and the mutant T7 RNA prepared in Example 2 were tested for enzyme activity.

[0203] 1. Relative enzyme activity detection

[0204] The reaction system for real-time fluorescence detection of the relative enzyme activity of T7 RNAP mutants is shown in Table 3. For detailed experimental methods, please refer to Chinese patent application number CN202211274914.8, entitled "A Method for Real-Time Monitoring of In Vitro Transcribed RNA." The added protein concentration and volume of T7 RNAP mutants were consistent with those of the wild-type, whose enzyme activity and protein concentration are known. The reaction was performed in a 96-well plate, and the fluorescence generated by the binding of the aptamer to DFHBI was measured in real time using a microplate reader. The reaction system was tailored to the experimental needs. The reaction conditions were 37°C. The real-time measurement was performed using a microplate reader for one hour, with values ​​measured every 1 minute. After the reaction, a graph was plotted using Origin software. The time at which the best linear relationship was achieved was used to calculate a standard curve of wild-type protein concentration versus fluorescence intensity, as shown in Figure 3. The relative enzyme activity of the mutants was then calculated. All reagents in the reaction system were prepared with nuclease-free HO, and all consumables used were RNase-free to prevent RNase degradation of the generated RNA.

[0205] Table 3 Reaction system for determining relative enzyme activity of different mutants by real-time fluorescence method

[0206] As shown in Tables 4-1, 4-2, and 4-3, the relative enzyme activity of the mutants, I217L, N579W, S397W, T121M, S223M, and R632G, at 37°C, was significantly improved compared to T7 RNAP-WT and significantly superior to the single-point mutants S430P, G47A+884G, S633P, and Q786L reported in the prior art. The combined mutant M8 exhibited significantly higher enzyme activity than the WT and the single-point mutants S430P, S633P, Q744R, Q786L, S43Y, and G47A+884G reported in the prior art. The relative activities of the combined mutants M7 and I217L / S397W / S430P / S633P / Q786L / N579W at 37°C were not different from those of T7 RNAP-WT. The relative activities of the combined mutants I217L / S397W / S430P / S633P / Q786L / Q744R and I217L / S397W / S430P / S633P / Q786L / C723E / A724N at 37°C were significantly better than those of T7 RNAP-WT, and the residual activities after heat treatment at 58°C for 15 min were significantly higher than those of T7 RNAP-WT. The residual activity of RNAP-WT was significantly higher than that of T7-RNAP-WT, single point mutant S430P, single point mutant S633P and single point mutant Q786L after treatment at 50°C for 5 min. The residual relative activity after heat treatment indicated that the combined mutants I217L / S397W / S430P / S633P / Q786L / Q744R and the combined mutants I217L / S397W / S430P / S633P / Q786L / C723E / A724N had higher thermal stability than the existing technology.

[0207] Table 4-1 Relative enzyme activity detection

[0208] Table 4-2 Relative enzyme activity detection

[0209] Table 4-3 Relative enzyme activity detection

[0210] 2. Determination of Tm value of T7 RNAP by differential scanning fluorimetry

[0211] Separately, 18 μL of T7 RNAP protein solution (0.2 mg / mL) was mixed with 2 μL of Sypro Orange dye (100×). The protein solution and Sypro Orange dye were diluted to the desired concentrations with PBS. The qPCR instrument was preheated for 20 minutes. The lid temperature was set to 100°C, the sample temperature was set to 25°C, the ramp rate was 0.5°C / s, and a 5-s wait time was used. The sample temperature was then cycled 120 times to 85°C. The filter was set to the Sypro Orange channel, and 10 samples were sampled and averaged. The Tm of a protein is an indicator of thermal stability. Generally speaking, the higher the Tm, the more stable the protein.

[0212] The results are shown in Table 5. The Tm values ​​of the single point mutant M369T and the single point mutant N579W were higher than those of WT. The Tm values ​​of the single point mutant I217L, the single point mutant S397W, the combined mutants M7 and M8, the combined mutants I217L / S397W / S430P / S633P / Q786L / N579W, the combined mutants I217L / S397W / S430P / S633P / Q786L / Q744R and the combined mutants I217L / S397W / S430P / S633P / Q786L / C723E / A724N were significantly higher than those of the wild type and other mutants (WT, S430P, S633P, Q786L) reported in the prior art, indicating that the above combined mutants are superior to the single point mutants and T7 reported in the prior art. RNAP-WT has higher thermal stability.

[0213] Table 5 Tm values ​​of wild-type and mutant T7 RNAP (℃)

[0214] 3. Comparison of IVT yield and product purity at different temperatures

[0215] The in vitro transcription (IVT) reaction system is shown in Table 6. The reaction system can be scaled up in equal proportions. After the system is configured, it is placed at 37°C and 50°C for 2 h, respectively. Then, 10 U of DNaseI is added to each reaction according to 1 μg of template and the reaction is carried out at 37°C for 30 min to digest the DNA template. The IVT product is then recovered by LiCl precipitation, and the RNA concentration is measured to calculate the mRNA yield (μg) corresponding to 1 μg of template DNA.

[0216] Table 6 In vitro transcription reaction system

[0217] The mRNA yield (μg) corresponding to 1μg template DNA is shown in Table 7-1. Under conventional 37°C reaction conditions, the IVT yield of the combined mutant M8 of the present invention is significantly improved compared to the wild-type WT and the single-point mutants S430P, S430P, Q786L, and G47A+884G reported in the prior art, and is comparable to the IVT yields of the mutants Q744R and S43Y reported in the prior art, and is also somewhat improved compared to the combined mutant M7. At the same time, under 50°C reaction conditions, the IVT yield of WT and Q786L reported in the prior art is significantly improved. The mutants 744R, S43Y, and G74A+884G produced almost no IVT products, indicating that WT, Q744R, S43Y, and G47A+884G could not tolerate the reaction at 50°C; the IVT yield of the combined mutant I217L / S397W / S430P / S633P / Q786L / N579W at 50°C increased by 60% compared with the IVT yield of WT at 37°C; the combined mutant I217L / S397W / S430P / S633P / Q786L / N579W at 50°C increased by 60% compared with the IVT yield of WT at 37°C; The IVT yield of L / Q744R at 37℃ or 50℃ was significantly improved compared with WT and single point mutants I217L, S397W, S430P, S633P, and Q786L. The IVT yield of the combined mutant I217L / S397W / S430P / S633P / Q786L / C723E / A724N at 37℃ was increased by about 20% compared with WT and single point mutants I217L, S430P, S633P, and Q786L. Right, the IVT yield of the reaction at 50°C was increased by about 120% compared with the IVT yield of WT and single-point mutants I217L, S430P, S633P, and Q786L at 37°C; the IVT yield of the combined mutant M8 at 50°C was significantly higher than that of the WT and mutants reported in the prior art, indicating that the combined mutants M8 and M7 have better IVT application performance, can produce higher yields of in vitro transcription products, can tolerate 50°C reactions, and have good thermal stability.

[0218] Table 7-1 IVT production

[0219] The product purities of the single mutants S430P, S633P, Q786L, I217L, S397W, the combined mutants M7, I217L / S397W / S430P / S633P / Q786L / N579W, I217L / S397W / S430P / S633P / Q786L / Q744R, and I217L / S397W / S430P / S633P / Q786L / C723E / A724N are shown in Table 7-2. The purity of the IVT product of N579W at 37°C was significantly improved compared with WT and single-point mutants I217L, S397W, S430P, S633P, and Q786L, and the product purity improvement rate was all above 10%; the purity of the product of the combination mutants I217L / S397W / S430P / S633P / Q786L / Q744R and the combination mutants I217L / S397W / S430P / S633P / Q786L / C723E / A724N at 37°C was significantly improved compared with WT and single-point mutants I217L, S397W, S430P, S633P, and Q786L, and the product purity improvement rate was all above 5%. Combined mutants I217L / S397W / S430P / S633P / Q786L, combined mutants I217L / S397W / S430P / S633P / Q786L / N579W, combined mutants I217L / S397W / S430P / S633P / Q786L / Q744R, and combined mutants I217L / S397W / S430P / S633 The purity of the IVT product of P / Q786L / C723E / A724N at 50°C was within 5% of the purity of the IVT product of WT and single-point mutants I217L, S397W, S430P, S633P, and Q786L at 37°C, and the purity of the IVT product of single-point mutants I217L, S397W, S430P, S633P, and Q786L at 50°C, indicating no significant difference. This indicates that the purity of the IVT product of the T7 RNAP mutant provided by the present invention is somewhat improved compared to the prior art.

[0220] Table 7-2 IVT product purity

[0221] 4. Comparison of dsRNA content in IVT products at different temperatures

[0222] The wild type WT, single mutants Q744R, S43Y, G47+884G, T121M, S223M, R632G, S430P, S633P, Q786L, I217L, S397W, combined mutants M7 and M8 were detected using our company's self-developed product dsRNA content ELISA quantitative detection kit. The purified IVT product RNA samples obtained in 3 were subjected to dsRNA content detection. The specific operation method is as follows: (1) The dsRNA standard was used to detect the dsRNA content of the purified IVT product RNA sample. Buffer was diluted to 8 concentrations, including 2pg / μL, 1pg / μL, 0.5pg / μL, 0.25pg / μL, 0.125pg / μL, 0.0625pg / μL, 0.0312pg / μL, and 0pg / μL. The purified RNA samples to be tested were diluted to 3 different concentration gradients, 10ng / μL, 5ng / μL, and 1ng / μL. (2) 100μL of each diluted standard and test sample were added to the microwells of the ELISA plate coated with dsRNA antibodies, and the plate was shaken at 500rpm for 60min at room temperature. (3) Add Wash the plate 4 times with 250 μL of washing solution, add 100 μL of biotinylated detection antibody at working concentration to each well, and shake the plate at 500 rpm for 60 minutes at room temperature; (4) After washing, add 100 μL of HRP-streptavidin at working concentration to each well, and shake at 500 rpm for 30 minutes; (4) Finally, add 100 μL of substrate colorimetric solution and react at room temperature in the dark for 30 minutes, then add 50 μL of stop solution to each well, and immediately perform the detection on the machine, set the dual wavelength of the microplate reader to 450 nm / 650 nm, and calculate the dsRNA content of the sample to be tested using the curve fitted by the standard.

[0223] The experimental results are shown in FIG4A , wherein the dsRNA content of the combined mutant M8 of the present invention in the unit mass IVT product of the conventional 37° C. reaction of the wild type WT, Q744R, S43Y and G47A+884G is significantly lower than that of the wild type WT and the single point mutants Q744R, S43Y, S430P, S633P, Q786L and M7 combined mutants reported in the prior art; in the unit mass IVT product of the in vitro transcription reaction at 50° C., the combined mutant of the present invention is significantly lower than that of the wild type WT and the single point mutants Q744R, S43Y, S430P, S633P, Q786L and M7 combined mutants reported in the prior art; The dsRNA content of variant M8 was significantly lower than that produced by reactions at 37°C. At 50°C, the dsRNA content per unit mass of IVT product was significantly reduced compared to the single-point mutants S430P, S633P, and Q786L reported in the prior art. Furthermore, the dsRNA content of its 50°C in vitro transcription product reached the same level as the G47A+884G mutant reported in CN111212905A, which reduced dsRNA contaminants and concatenated transcripts in in vitro transcription products. At 50°C, the combined mutant M8 of the present invention exhibited even lower dsRNA content per unit mass of IVT product than the combined mutant M7. Since the wild-type WT, mutants Q744R, S43Y, G47A+884G, T121M, S223M, and R632G produced virtually no IVT product at 50°C, their dsRNA contents at 50°C are not presented in the results.

[0224] The dsRNA content in the IVT products of the wild type WT, single mutants S430P, S633P, Q786L, I217L, S397W, and combination mutants I217L / S397W / S430P / S633P / Q786L, I217L / S397W / S430P / S633P / Q786L / N579W, I217L / S397W / S430P / S633P / Q786L / Q744R, and I217L / S397W / S430P / S633P / Q786L / C723E / A724N was detected by dot blot. The IVT RNA samples recovered by LiCl precipitation obtained in step 3 were added dropwise to a positively charged Hybond N membrane (GE Healthcare). The membrane was then blocked with 5% (w / v) nonfat dry milk in TBS-T buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% v / v Tween-20). The blot was then incubated with J2 anti-dsRNA antibody at a 1:5000 dilution at 4°C overnight. The blot was probed with an HRP-conjugated secondary antibody (Cell Signaling Technologies). A dsRNA standard with known concentrations served as a positive control.

[0225] The experimental results are shown in Figure 4B. When the mRNA loading amount is consistent, the dot Blot analysis showed that the dsRNA byproduct content in the IVT products of single point mutants I217L, S397W, S430P, S633P, Q786L, combination mutants I217L / S397W / S430P / S633P / Q786L, combination mutants I217L / S397W / S430P / S633P / Q786L / N579W, combination mutants I217L / S397W / S430P / S633P / Q786L / Q744R, and combination mutants I217L / S397W / S430P / S633P / Q786L / C723E / A724N reacted at 50°C was significantly lower than that in the IVT product of WT reacted at 37°C. This indicates that the T7 RNAP mutant provided in the above examples has a significantly improved dsRNA content in the IVT product compared to the wild type in the prior art through high temperature reaction.

[0226] 5. 3' end consistency detection of IVT products at different temperatures

[0227] The 3' end consistency test of IVT products is achieved through RNase T1 digestion experiments. RNase T1 can specifically degrade single-stranded RNA at the G residue. It forms the corresponding intermediate 2', 3'-cyclic phosphate (-mP) salt, cleaving the phosphodiester bond between the 3'-guanosine residue and the 5'-OH residue of the adjacent nucleotide; the reaction products are 3'-GMP and oligonucleotides containing terminal 3'-GMP. Then, the molecular weight of the 3' end product is analyzed by LC-MS and compared with the theoretical molecular weight. If the 3' end of the normal mRNA product is a G base ending in -OH, then the 3' end G base of the heterogeneous product ends in -mP, and the molecular weight of the heterogeneous product is 80 more than that of the normal product. The 3' end consistency (%) is calculated by analyzing the proportion of the theoretical molecular weight product.

[0228] The experimental results are shown in Figures 5A to 5J. The molecular weight of the pure product with 3' end consistency is 9663.1, and the molecular weight of the 3' end heterogeneous conjugation product is 9743.1. Figures 5A to 5J are the results of LC-MS analysis of 3' end products of IVT products of wild type WT (37°C), Q774R (37°C), S43Y (37°C), G47A+884G (37°C), M7 (37°C), M7 (50°C), M8 (37°C), M8 (50°C), I217L (50°C), and S397W (50°C). The detailed data analysis is shown in Table 8. Since almost no IVT products are produced at 50°C for the wild type WT, mutants Q744R, S43Y, and G47A+884G, their 3' end consistency at 50°C is not shown in the results. The 3' end consistency product of the combined mutant M8 of the present invention at 37°C was significantly better than that of the WT, the single point mutant Q744R, and the combined mutant M7. The 3' end consistency product of the combined mutant M8 at 50°C was significantly better than that of the single point mutant S43Y and the mutant G47A+884G at 37°C. This indicates that the T7 RNAP combined mutant M8 provided by the present invention can not only withstand 50°C reaction, but also has significantly improved 3' end consistency of the IVT product compared with the prior art.

[0229] Table 8 IVT product 3' end consistency

[0230] “ / ” indicates that the wild-type WT or mutant produced almost no IVT product at 50°C, so the 3' end identity at 50°C was not shown in the results.

[0231] 6. Cellular response detection of IVT products at different temperatures

[0232] Cellular immune responses to dsRNA byproducts may lead to adverse consequences. Purified IVT product RNA samples were used for cellular response detection. The specific operation method is as follows: (1) Thaw the cryopreserved tube containing the raw cell suspension and mix it evenly. Add the cell suspension to a culture flask or culture dish containing culture medium and culture overnight. When the density of the raw cells reaches 80%-90%, subculture them. (2) Inoculate cells: Prepare IVT product-lipid complexes and transfect cells using the cationic liposome transfection reagent Lipofectamine 3000. Among them, Polycytidylic acid (Poly (I:C)) and Resiquimod (R848) are used as positive controls, transfection reagent alone is used as a negative control, and no transfection treatment is used as a blank control. (3) After 48 hours of culture, serum was collected and IFN-α and IL-6 cytokines in cell serum were quantitatively detected using the IFN alpha Mouse ELISA Kit (Thermo Scientific) and the mouse IL-6 double antibody sandwich ELISA detection kit (Proteintech Group). The measured concentrations of the test samples were calculated using the curves fitted by the standard samples. Finally, the IL-6 and IFN-α expression of the IVT products of the T7 RNAP mutant at different temperatures was obtained. IFN-α and IL-6 are cytokines produced by the body's immune cells. They are immune response factors produced by immune cells through immune response when the body is infected. The levels of IFN-α and IL-6 detected in this study reflect the immunogenicity of the T7 RNA polymerase IVT products.

[0233] The experimental results are shown in Figures 6A and 6B. By comparing the intracellular IFN-α and IL-6 factor levels caused by the IVT products of the wild-type WT and mutant M8: I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y, it was found that among the four different transcription templates, the IFN-α and IL-6 factor levels caused by the IVT products of M8 at 37°C and 50°C were lower than those of the wild-type WT, indicating that the mRNA obtained by the in vitro transcription reaction of the T7 RNA polymerase mutant M8 provided by the present invention has lower immunogenicity than that of the wild-type WT.

[0234] Example 4: T7 RNAP mutants with improved performance

[0235] According to the methods of Examples 2 and 3, partial site-directed mutagenesis was performed at amino acid positions 217, 397, 121, 223, and 632 of the amino acid sequence of wild-type T7 RNAP (shown in SEQ ID NO. 1), and T7 RNAP mutants were prepared. Changes in their activities were detected (activity changes were detected using the relative activity detection method of Example 3, and the Tm values ​​of each mutant were determined using the differential scanning fluorimetry of Example 3. The Tm value reflects the stability of each mutant protein; the higher the Tm value, the more stable the protein).

[0236] Table 9-1 Site-directed mutagenesis at different sites

[0237] Table 9-2 Site-directed mutagenesis at different sites

[0238] The results are shown in Table 9-1 and Table 9-2. The results show that after the 786th position mutated to M or F, the 217th position mutated to A or V, the 397th position mutated to P, and the 579th position mutated to A or D, the enzyme activity and Tm value at 37°C were higher than those of the mutants S430P, S633P, Q786L, G47A+884G and T7 RNAP-WT reported in the prior art; after the 121st position mutated to L or S, the 223rd position mutated to L or V, and the 632nd position mutated to E, the enzyme activity at 37°C was significantly improved compared with the mutants reported in the prior art and T7 RNAP-WT, and the Tm value after the 369th position mutated to E was also improved to a certain extent compared with the wild-type T7 RNAP and the mutants reported in the prior art. These results indicate that T7 RNAP mutants harboring mutations at the Q786M, Q786F, I217A, I217V, S397P, N579A, and M369E sites exhibit higher thermostability than wild-type T7 RNAP. Mutants I121L, I121S, S223L, S223V, and R632E sites, while lacking significant thermostability advantages over wild-type T7 RNAP, exhibit higher enzymatic activity. These mutants have broad application prospects in in vitro transcription, mRNA vaccine and drug research and production, gene editing, isothermal amplification, in vivo protein expression, and cell-free protein expression in vitro translation systems.

[0239] Example 5: T7-RNA mutation sites with high sequence similarity

[0240] RNA polymerases from different sources with an amino acid identity of more than 80% were compared, and the results are shown in Figures 7A to 7E. It was found that part of the sequence was highly conserved, including positions 217, 223, 397, 579, and 632. When the amino acid substitutions at positions 217, 223, 397, 579, and 632 described in the present application are transferred to the corresponding positions in other closely related phage RNA polymerases (SEQ ID NO.29 to SEQ ID NO.62), it is expected to have the same effect. The amino acid sequences of the closely related phage RNA polymerases (SEQ ID NO.29 to SEQ ID NO.62) are similar to those of SEQ ID NO.29 in Examples 1-4. The wild-type amino acid sequence of T7 phage RNA polymerase shown in NO.1 has 97.96%, 98.07%, 98.64%, 98.07%, 98.19%, 90.26%, 97.51%, 97.40%, 97.40%, 98.19%, 98.53%, 82.35%, 98.75%, 97.73%, 82.47%, 98 .41%, 92.98%, 82.47%, 98.41%, 82.47%, 98.30%, 98.41%, 98.19%, 98.53%, 89.92%, 82.69%, 82.58%, 82.47%, 82.47%, 82.35%, 82.47%, 82.24%, 82.13%, 82.01% sequence identity.

[0241] The amino acid substitutions at positions 121 and 369 are expected to have the same effect when transferred to the corresponding positions in other closely related phage RNA polymerases. The closely related phage RNA polymerase amino acid sequences at position 121 (SEQ ID NO. 29 to SEQ ID NO. 39, SEQ ID NO. 41 to SEQ ID NO. 42, SEQ ID NO. 44 to SEQ ID NO. 45, SEQ ID NO. 47, and SEQ ID NO. 49 to SEQ ID NO. 53) have 97.96%, 98.07%, 98.64%, 98.07%, 98.19%, 90.26%, 97.51%, 97.40%, 97.40%, 98.19%, 98.535%, 98.75%, 97.73%, 98.41%, 98.30%, 98.41%, 98.19%, 98.53%, and 89.92% sequence identity with the wild-type T7 phage RNA polymerase amino acid sequence set forth in SEQ ID NO. 1 of Examples 1-4, respectively. The closely related phage RNA polymerase amino acid sequence SEQ ID NO. 44 at position 369 has a sequence identity of 98.41% with the wild-type amino acid sequence of T7 phage RNA polymerase shown in SEQ ID NO. 1 in Example 1-4.

[0242] The amino acid sequence of the wild-type parent T7 RNA polymerase of the present invention (SEQ ID NO.1):

[0243] Although the present invention has been disclosed above in terms of preferred embodiments, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A RNA polymerase mutant with improved performance, characterized in that: The RNA polymerase mutant has one or more amino acid mutations at positions 121, 223, 632, 217, 397, 369, and 579 based on the amino acid sequence corresponding to the parent RNA polymerase, or one or more amino acid mutations occur at the amino acid residues at equivalent positions in the parent RNA polymerase; the amino acid sequence of the parent RNA polymerase has at least 80% identity with the amino acids shown in SEQ ID NO.1 and has RNA polymerase activity.

2. The RNA polymerase mutant according to claim 1, characterized in that The RNA polymerase mutant also has one or more amino acid mutations at position 430, 633, 786, 744, 724, 43 or 723.

3. The RNA polymerase mutant according to any one of claims 1 to 2, characterized in that: Corresponding to the amino acid sequence shown in SEQ ID NO.1, The amino acid at position 217 is mutated to L, A or V; preferably, mutated to L; The amino acid at position 397 is mutated to W, A or P; preferably, it is mutated to W; The amino acid at position 121 is mutated to M, L or S; preferably, it is mutated to M; The amino acid at position 223 is mutated to M, P, L, V or F; preferably, mutated to M; The amino acid at position 632 is mutated to G or E; preferably, mutated to G; The amino acid at position 369 is mutated to T or E; The amino acid at position 579 mutates to A, W or D; preferably, mutates to W.

4. The RNA polymerase mutant according to claim 2, characterized in that Corresponding to the amino acid sequence shown in SEQ ID NO.1, The amino acid at position 430 is mutated to a non-polar hydrophobic amino acid; optionally, it is mutated to P, L, V, M, or F; preferably, it is mutated to P; The amino acid at position 633 is mutated to a non-polar hydrophobic amino acid; optionally, it is mutated to P, L, V, M or F, A, I, W; preferably, it is mutated to P; The amino acid at position 786 is mutated to a non-polar hydrophobic amino acid or Y; alternatively, it is mutated to P, I, A, V, Y, L, M, W or F; preferably, it is mutated to L; The amino acid at position 744 is mutated to R, P or L; preferably, mutated to R; The amino acid at position 43 is mutated to Y or A; preferably, mutated to Y; The amino acid at position 723 is mutated to E or S; preferably, mutated to E; The amino acid at position 724 is mutated to N; Preferably, the RNA polymerase mutant simultaneously has at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P and Q786L, named I217L / S397W / S430P / S633P / Q786L; Preferably, the RNA polymerase mutant simultaneously has at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P, Q786L, N579W, named I217L / S397W / S430P / S633P / Q786L / N579W; Preferably, the RNA polymerase mutant simultaneously has at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P, Q786L, Q744R, named I217L / S397W / S430P / S633P / Q786L / Q744R; Preferably, the RNA polymerase mutant simultaneously has at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P, Q786L, C723E, A724N, named I217L / S397W / S430P, S633P / Q786L / C723E / A724N; Preferably, the RNA polymerase mutant simultaneously has at least the following mutations equivalent to or corresponding to the parent polymerase mutant: I217L, S397W, S430P, S633P, Q786L, Q744R, S43Y, named I217L / S397W / S430P / S633P / Q786L / Q744R / S43Y.

5. A polynucleotide encoding the RNA polymerase mutant according to any one of claims 1 to 4.

6. A vector carrying the polynucleotide of claim 5 or a cell expressing the RNA polymerase mutant of any one of claims 1 to 4.

7. A method for synthesizing a polynucleotide, characterized in that: Use of the RNA polymerase mutant according to any one of claims 1 to 4; wherein the synthesis method comprises in vitro transcription synthesis, isothermal amplification or transcription-mediated amplification.

8. Use of the RNA polymerase mutant according to any one of claims 1 to 4 or the method for synthesizing the polynucleotide according to claim 6 in the preparation of mRNA vaccines, the preparation of nucleic acid drugs, gene editing or the construction of protein expression systems.

9. A polynucleotide synthesis kit, characterized in that: The invention comprises the RNA polymerase mutant according to any one of claims 1 to 4.

10. A method for improving at least one property of an RNA polymerase, wherein the property is selected from the group consisting of enzyme activity, thermal stability, 3' end identity, in vitro transcription yield, dsRNA byproducts, and immunogenicity, characterized in that: Based on the amino acid sequence corresponding to the parent RNA polymerase, one or more amino acid mutations occur at positions 121, 223, 632, 217, 397, 369, and 579, or one or more amino acid mutations occur at the amino acid residues at equivalent positions in the parent RNA polymerase; the amino acid sequence of the parent RNA polymerase has at least 80% identity with the amino acids shown in SEQ ID NO.1 and has RNA polymerase activity.

11. A method for screening T7 RNA polymerase mutants, characterized in that: The method comprises amplifying a polynucleotide encoding T7 RNA polymerase in a reaction system containing 0.1 to 0.6 mM manganese ions, then transforming a vector carrying the amplified product into cells, inducing expression in the cells and sorting target cells using a droplet microfluidic cell sorting method; in an in vitro incubation step of the droplet microfluidic cell sorting, heat-treating the droplets; Preferably, the heat treatment is carried out at 40-50°C for 5-10 minutes; Preferably, the heat treatment condition is 45°C for 7 minutes; Preferably, the manganese ion concentration in the reaction system is 0.2 mM to 0.3 mM; Preferably, the target cells are 0.4% to 0.45% of the droplet-encapsulated cells that exhibit the highest viability; Preferably, the amplified polynucleotide encoding T7 RNA polymerase and the nucleotide sequence are shown as SEQ ID NO.15; Preferably, the method further comprises at least one step: separating the target fragments from the target cells sorted by the droplet microfluidic cell sorting method, transforming the fragments into another cell, and screening the cells again after culturing; Preferably, the T7 RNA polymerase mutants expressed by the positive cells are collected, the system containing the T7 RNA polymerase mutants is heat-treated, and then the enzyme activity is determined, and the positive clones whose enzyme activity is at least 1.5 times that of the wild type are sequenced.

Citation Information

Patent Citations

  • RNA polymerase mutant with improved functions

    CN102177236A

  • T7 rna polymerase variants with expanded substrate range and enhanced transcriptional yield

    CN106459879A

  • T7-RNA polymerase mutant and application thereof

    CN112831484A

  • Mutated t7 RNA polymerases

    US20150024435A1

  • RNA polymerase variants for co-transcriptional capping

    US20210309976A1

Cited By

  • Heat-resistant high-yield T7 RNA polymerase mutant as well as preparation method and application thereof

    CN119752838A

  • T7 RNA polymerase mutant as well as preparation method and application thereof

    CN121204002A